CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03425461
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:14.225809+00:00
- Published At
- 2021-04-02T00:00:00+00:00
- Record Updated At
- 2021-04-02
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-04-02"- protocolSection.identificationModule.nctId
"NCT03425461"- protocolSection.identificationModule.officialTitle
"Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.